Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Pilot study of serial FLT and FDG-PET/CT imaging to monitor response to neoadjuvant chemoradiotherapy of esophageal adenocarcinoma: correlation with histopathologic response

Pilot study of serial FLT and FDG-PET/CT imaging to monitor response to neoadjuvant... Objective The aim of this prospective pilot study was to investigate the potential of serial FLT-PET/CT compared to FDG- PET/CT to provide an early indication of esophageal cancer response to concurrent neoadjuvant chemoradiation therapy. Methods Five patients with biopsy-proven esophageal adenocarcinomas underwent neoadjuvant chemoradiation (Tx) prior to minimally invasive esophagectomy. The presence of residual tumor was classified histologically using the Mandard et al. criteria, categorizing patients as pathologic responders and non-responders. Participants underwent PET/CT imaging 1 h after intravenous administration of FDG and of FLT on two separate days within 48 h of each other. Each patient underwent a total of 3 scan “pairs”: (1) pre-treatment, (2) during treatment, and (3) post-treatment. Image-based response to therapy was measured in terms of changes in SUVmax (ΔSUV) between pre- and post-therapeutic FLT- and FDG-PET scans. The PET imaging findings were correlated with the pathology results after surgery. Results All tumors were FDG and FLT avid at baseline. Lesion FLT uptake was lower than with FDG. Neoadjuvant chemo- radiation resulted in a reduction of tumor uptake of both radiotracers in pathological responders (n = 3) and non-responders (n = 2). While the difference in the reduction in mean tumor FLT uptake during Tx between responders http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of Nuclear Medicine Springer Journals

Pilot study of serial FLT and FDG-PET/CT imaging to monitor response to neoadjuvant chemoradiotherapy of esophageal adenocarcinoma: correlation with histopathologic response

Loading next page...
1
 
/lp/springer_journal/pilot-study-of-serial-flt-and-fdg-pet-ct-imaging-to-monitor-response-QV5eA16860

References (36)

Publisher
Springer Journals
Copyright
Copyright © 2018 by The Japanese Society of Nuclear Medicine
Subject
Medicine & Public Health; Nuclear Medicine; Imaging / Radiology
ISSN
0914-7187
eISSN
1864-6433
DOI
10.1007/s12149-018-1229-0
pmid
29332233
Publisher site
See Article on Publisher Site

Abstract

Objective The aim of this prospective pilot study was to investigate the potential of serial FLT-PET/CT compared to FDG- PET/CT to provide an early indication of esophageal cancer response to concurrent neoadjuvant chemoradiation therapy. Methods Five patients with biopsy-proven esophageal adenocarcinomas underwent neoadjuvant chemoradiation (Tx) prior to minimally invasive esophagectomy. The presence of residual tumor was classified histologically using the Mandard et al. criteria, categorizing patients as pathologic responders and non-responders. Participants underwent PET/CT imaging 1 h after intravenous administration of FDG and of FLT on two separate days within 48 h of each other. Each patient underwent a total of 3 scan “pairs”: (1) pre-treatment, (2) during treatment, and (3) post-treatment. Image-based response to therapy was measured in terms of changes in SUVmax (ΔSUV) between pre- and post-therapeutic FLT- and FDG-PET scans. The PET imaging findings were correlated with the pathology results after surgery. Results All tumors were FDG and FLT avid at baseline. Lesion FLT uptake was lower than with FDG. Neoadjuvant chemo- radiation resulted in a reduction of tumor uptake of both radiotracers in pathological responders (n = 3) and non-responders (n = 2). While the difference in the reduction in mean tumor FLT uptake during Tx between responders

Journal

Annals of Nuclear MedicineSpringer Journals

Published: Jan 13, 2018

There are no references for this article.